Table 5.
Summary of recent studies of HIFU monotherapy for advanced pancreatic cancer
| Study | Pts | Characteristics of pts | Pain relief (%) | ORR (%) | MST (months) | 6-month OS | 12-month OS | 24-month OS |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Zhao et al 201741 | 38 | Unresectable, locally advanced; tumor size unclear | – | – | 10.8 | 100% | 36.40% | – |
| Marinova et al 201844 | 50 | Unresectable, advanced; tumor size unclear | 84% | – | 16.2 | – | – | – |
| Wang et al 201118 | 40 | Unresectable, advanced; tumor size 4.3 cm | 87.50% | – | 8 | 58.80% | 30.10% | – |
| Sung et al 201119 | 46 | Unresectable, advanced; tumor size 4.2 cm | – | 77.50% | 12.4 | 52.20% | 30.40% | – |
| Xiong et al 200945 | 89 | Unresectable; tumor size unclear | 80% | 14.60% | 11.2 for stage III 5.4 for stage IV |
41.0% 6.5% |
– | 10.3% 0% |
| Li et al 201246 | 25 | Unresectable, advanced; tumor size unclear | 92% | – | 10 | – | 42% | |
| Zhou 201414,a | 653 | Unresectable, advanced; tumor size unclear | 71% | CR: 29.66% PR: 39.83% |
10.03 | – | – | |
Note:
a
This article was a review of HIFU for advanced pancreatic cancer.
Abbreviations: CR, complete response; HIFU, high-intensity focused ultrasound; MST, median survival time; ORR, objective response rate; PR, partial response; pts, patients HIFU, high-intensity focused.